Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Dippold JP, Ja WG. Realizing Paul Ehrlich's magic bullets. J Cancer Res Clin Oncol 1989;115:494-5
   Web of Science ®Google Scholar
• Bodey B, Siegel SE, Kaiser HE. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Anticancer Res 1996;16:661-74
   PubMed Web of Science ®Google Scholar
• Pastan I, Hassan R, FitzGerald DJ, Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221-37
   PubMed Web of Science ®Google Scholar
• Kreitman RJ. Immunotoxins in cancer therapy. Curr Opin Immunol 1999;11:570-8
   PubMed Web of Science ®Google Scholar
• Reiter Y, Pastan I. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol 1998;16:513-20
   PubMed Web of Science ®Google Scholar
• Reiter Y. Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res 2001;81:93-124
   PubMed Web of Science ®Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106
   PubMed Web of Science ®Google Scholar
• Mazzolini G, Murillo O, Atorrasagasti C, Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol 2007;13:5822-31
   PubMed Web of Science ®Google Scholar
• Kocak E, Lute K, Chang X, Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 2006;66:7276-84
   PubMed Web of Science ®Google Scholar
• Jain RK, Koenig GC, Dellian M, Leukocyte-endothelial adhesion and angiogenesis in tumors. Cancer Metastasis Rev 1996;15:195-204
   PubMed Web of Science ®Google Scholar
• Pastan I. Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol Immunother 2003;52:338-41
   PubMed Web of Science ®Google Scholar
• Pai-Scherf LH, Villa J, Pearson D, Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 1999;5:2311-5
   PubMed Web of Science ®Google Scholar
• Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-29
   PubMed Web of Science ®Google Scholar
• Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548-57
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85
   PubMed Web of Science ®Google Scholar
• Zhang W, Gordon M, Lenz HJ. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann Med 2006;38:545-51
   PubMed Web of Science ®Google Scholar
• Wainberg Z, Hecht JR. Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opin Biol Ther 2006;6:1229-35
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8
   PubMed Web of Science ®Google Scholar
• Galizia G, Lieto E, De Vita F, Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007;26:3654-60
   PubMed Web of Science ®Google Scholar
• Maiello E, Giuliani F, Gebbia V, Cetuximab: clinical results in colorectal cancer. Ann Oncol 2007;18(Suppl 6):vi8-10
   PubMedGoogle Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-9
   PubMed Web of Science ®Google Scholar
• Javle M, Hsueh C-T. Updates in gastrointestinal oncology–insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 2009;2:9
   PubMedGoogle Scholar
• Balko JM, Black EP. A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer 2009;9:145
   PubMedGoogle Scholar
• Loupakis F, Ruzzo A, Cremolini C, KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009
   Google Scholar
• Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-33
   PubMed Web of Science ®Google Scholar
• Giusti RM, Shastri KA, Cohen MH, FDA drug approval summary: panitumumab (Vectibix). Oncologist 2007;12:577-83
   PubMed Web of Science ®Google Scholar
• Rivera F, Salcedo M, Vega N, Current situation of zalutumumab. Expert Opin Biol Ther 2009;9:667-74
   PubMed Web of Science ®Google Scholar
• Capdevila J, Saura C, Macarulla T, Monoclonal antibodies in the treatment of advanced colorectal cancer. Eur J Surg Oncol 2007;33(Suppl 2):S24-34
   PubMedGoogle Scholar
• Pastan II, Kreitman RJ. Immunotoxins for targeted cancer therapy. Adv Drug Deliv Rev 1998;31:53-88
   PubMed Web of Science ®Google Scholar
• Masui H, Kamrath H, Apell G, Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res 1989;49:3482-8
   PubMed Web of Science ®Google Scholar
• Taetle R, Honeysett JM, Houston LL. Effects of anti-epidermal growth factor (EGF) receptor antibodies and an anti-EGF receptor recombinant-ricin A chain immunoconjugate on growth of human cells. J Natl Cancer Inst 1988;80:1053-9
   PubMed Web of Science ®Google Scholar
• Hirota N, Ueda M, Ozawa S, Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. Cancer Res 1989;49:7106-9
   PubMed Web of Science ®Google Scholar
• Heisler I, Sutherland M, Bachran C, Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells. J Control Release 2005;106:123-37
   PubMed Web of Science ®Google Scholar
• Yip WL, Weyergang A, Berg K, Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells. Mol Pharm 2007;4:241-51
   PubMedGoogle Scholar
• Schuell B, Gruenberger T, Scheithauer W, HER 2/neu protein expression in colorectal cancer. BMC Cancer 2006;6:123
   PubMed Web of Science ®Google Scholar
• Nathanson DR, Culliford AT, Shia J, HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 2003;105:796-802
   PubMed Web of Science ®Google Scholar
• Osako T, Miyahara M, Uchino S, Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998;55:548-55
   PubMed Web of Science ®Google Scholar
• Kapitanovic S, Radosevic S, Kapitanovic M, The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997;112:1103-13
   PubMed Web of Science ®Google Scholar
• Moulder SL, Arteaga CL. A Phase I/II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpresses HER2/neu (ErbB-2). Clin Breast Cancer 2003;4:142-5
   PubMedGoogle Scholar
• Kreitman RJ. Recombinant fusion toxins for cancer treatment. Expert Opin Biol Ther 2002;2:785-91
   PubMed Web of Science ®Google Scholar
• Stish BJ, Chen H, Shu Y, Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 2007;13:3058-67
   PubMed Web of Science ®Google Scholar
• Giannopoulou E, Antonacopoulou A, Floratou K, Dual targeting of EGFR and HER-2 in colon cancer cell lines. Cancer Chemother Pharmacol 2009;63:973-81
   PubMed Web of Science ®Google Scholar
• Azemar M, Djahansouzi S, Jager E, Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat 2003;82:155-64
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Harder S, Hovelmann S, Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res 2005;7:R617-626
   PubMed Web of Science ®Google Scholar
• Shinohara H, Morita S, Kawai M, Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. J Surg Res 2002;102:169-77
   PubMed Web of Science ®Google Scholar
• Mazor Y, Noy R, Wels WS, chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts. Cancer Lett 2007;257:124-35
   Google Scholar
• Schmidt M, Hynes NE, Groner B, A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor. Int J Cancer 1996;65:538-46
   PubMed Web of Science ®Google Scholar
• De Lorenzo C, Nigro A, Piccoli R, A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. FEBS Lett 2002;516:208-12
   PubMed Web of Science ®Google Scholar
• De Lorenzo C, Arciello A, Cozzolino R, A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res 2004;64:4870-4
   PubMed Web of Science ®Google Scholar
• Rhee J, Hoff PM. Angiogenesis inhibitors in the treatment of cancer. Expert Opin Pharmacother 2005;6:1701-11
   PubMed Web of Science ®Google Scholar
• Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 2004;4(Suppl 2):S62-8
   PubMedGoogle Scholar
• Bang S, Nagata S, Onda M, HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005;11:1545-50
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiang L, Hassan R, I: immunotoxin and taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci USA 2007;104:17099-104
   PubMed Web of Science ®Google Scholar
• Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 2001;47:624-30
   PubMed Web of Science ®Google Scholar
• Schmitz J, Reali E, Hodge JW, Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res 2002;62:5058-64
   PubMed Web of Science ®Google Scholar
• Lutterbuese R, Raum T, Kischel R, Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother 2009;32:341-52
   PubMed Web of Science ®Google Scholar
• Conaghan P, Ashraf S, Tytherleigh M, Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen. Br J Cancer 2008;98:1217-25
   PubMed Web of Science ®Google Scholar
• Tsai LC, Chen YL, Lee C, Growth suppression of human colorectal carcinoma in nude mice by monoclonal antibody C27-abrin A chain conjugate. Dis Colon Rectum 1995;38:1067-74
   PubMed Web of Science ®Google Scholar
• Manosroi J, von Kleist S, Manosroi A, Thermo-stability and antitumor activity on colon cancer cell lines of monoclonal anti-CEA antibody-saporin immunotoxin. J Korean Med Sci 1992;7:128-35
   PubMedGoogle Scholar
• Akamatsu Y, Murphy JC, Nolan KF, A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells. Clin Cancer Res 1998;4:2825-32
   PubMed Web of Science ®Google Scholar
• He D, Yang H, Lin Q, Arg9-peptide facilitates the internalization of an anti-CEA immunotoxin and potentiates its specific cytotoxicity to target cells. Int J Biochem Cell Biol 2005;37:192-205
   PubMed Web of Science ®Google Scholar
• Wong JY, Chu DZ, Williams LE, Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res 2004;10:5014-21
   PubMed Web of Science ®Google Scholar
• Liersch T, Meller J, Bittrich M, Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol 2007;14:2577-90
   PubMed Web of Science ®Google Scholar
• Wong JY, Shibata S, Williams LE, A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003;9:5842-52
   PubMed Web of Science ®Google Scholar
• Wong JY, Chu DZ, Williams LE, A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother Radiopharm 2006;21:88-100
   PubMed Web of Science ®Google Scholar
• Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res 2003;9:3973S-81S
   PubMed Web of Science ®Google Scholar
• Lisovenko SG, Kolesnik EA, Kikot VV. Application of tumor marker antigens on immunotherapy of patients with colorectal cancer. Exp Oncol 2002;24:258-64
   Web of Science ®Google Scholar
• Punt CJ, Nagy A, Douillard JY, Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002;360:671-7
   PubMed Web of Science ®Google Scholar
• Aigner S, Ramos CL, Hafezi-Moghadam A, CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 1998;12:1241-51
   PubMed Web of Science ®Google Scholar
• Sagiv E, Memeo L, Karin A, CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 2006;131:630-9
   PubMed Web of Science ®Google Scholar
• Sagiv E, Kazanov D, Arber N. CD24 plays an important role in the carcinogenesis process of the pancreas. Biomed Pharmacother 2006;60:280-4
   PubMed Web of Science ®Google Scholar
• Sagiv E, Arber N. The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy. Expert Rev Gastroenterol Hepatol 2008;2:125-33
   PubMedGoogle Scholar
• Sagiv E, Starr A, Rozovski U, Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res 2008;68:2803-12
   PubMed Web of Science ®Google Scholar
• Benkerrou M, Jais JP, Leblond V, Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998;92:3137-47
   PubMed Web of Science ®Google Scholar
• Mazor Y, Barnea I, Keydar I, Antibody internalization studied using a novel IgG binding toxin fusion. J Immunol Methods 2007;321:41-59
   PubMed Web of Science ®Google Scholar
• Schnell R, Katouzi AA, Linnartz C, Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice. Int J Cancer 1996;66:526-31
   PubMed Web of Science ®Google Scholar
• Zangemeister-Wittke U, Lehmann HP, Waibel R, Action of a CD24-specific deglycosylated ricin-A-chain immunotoxin in conventional and novel models of small-cell-lung-cancer xenograft. Int J Cancer 1993;53:521-8
   PubMed Web of Science ®Google Scholar
• Onda M, Beers R, Xiang L, An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 2008;105:11311-6
   PubMed Web of Science ®Google Scholar
• Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003;23:3S-8S
   PubMed Web of Science ®Google Scholar